<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human mitochondria can be studied either in biopsies or by measuring flux through ATP synthase and phosphocreatine recovery using magnetic resonance spectroscopy </plain></SENT>
<SENT sid="1" pm="."><plain>Myocellular ATP production (flux through ATP synthase [fATP]) increases by up to 90% during 8 h of insulin stimulation </plain></SENT>
<SENT sid="2" pm="."><plain>Fasting <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function is 14-40% lower than in controls in the presence of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, as seen in those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, their insulin-resistant relatives or the <z:mp ids='MP_0001261'>obese</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin-stimulated fATP is abolished in insulin-resistant relatives and patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and patients frequently show decreased <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> size/density </plain></SENT>
<SENT sid="4" pm="."><plain>Age, fat mass, physical activity, plasma NEFA and <z:chebi fb="105" ids="17234">glucose</z:chebi> <z:hpo ids='HP_0000001'>all</z:hpo> correlate negatively with <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function, but it is for methodological reasons difficult to determine whether reduced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> content or function account for reduced ATP production in <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Experimental plasma NEFA elevation appears to inhibit <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function by interfering with the metabolic actions of insulin, which might explain impaired <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function in <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Alternatively, primary <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> abnormalities, as seen in those with inherited risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, could decrease <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation, thereby raising circulating and intracellular NEFA levels </plain></SENT>
<SENT sid="7" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> could first diminish the function, and subsequently reduce the size or density of mitochondria via <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="?"><plain>Many questions remain unsolved, including (1) which mechanisms regulate <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> adaptation to nutrient overload; (2) what factors control the expression of genes encoding <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> proteins and other signals involved in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> biogenesis; (3) which geno/phenotypes are associated with both <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> abnormalities; and (4) which are the most promising targets for improving <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> fitness in <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>